Creative Planning Purchases 22,171 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Creative Planning boosted its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 83.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 48,611 shares of the medical technology company’s stock after acquiring an additional 22,171 shares during the period. Creative Planning’s holdings in Alphatec were worth $270,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Magnetar Financial LLC bought a new stake in shares of Alphatec during the second quarter valued at about $10,957,000. First Eagle Investment Management LLC bought a new stake in shares of Alphatec during the second quarter valued at about $1,071,000. Lighthouse Investment Partners LLC increased its position in shares of Alphatec by 257.5% during the second quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company’s stock valued at $2,180,000 after buying an additional 150,244 shares during the period. BNP Paribas Financial Markets increased its position in shares of Alphatec by 276.1% during the first quarter. BNP Paribas Financial Markets now owns 99,790 shares of the medical technology company’s stock valued at $1,376,000 after buying an additional 73,257 shares during the period. Finally, Granite Investment Partners LLC increased its position in shares of Alphatec by 130.2% during the second quarter. Granite Investment Partners LLC now owns 664,201 shares of the medical technology company’s stock valued at $6,941,000 after buying an additional 375,621 shares during the period. 66.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ATEC shares. Stifel Nicolaus decreased their price target on Alphatec from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $13.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Wells Fargo & Company decreased their price objective on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Finally, Lake Street Capital decreased their price objective on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and an average target price of $17.00.

Alphatec Stock Down 0.1 %

Shares of ATEC opened at $9.40 on Friday. The firm has a market cap of $1.33 billion, a P/E ratio of -7.34 and a beta of 1.31. The stock has a 50 day simple moving average of $6.07 and a two-hundred day simple moving average of $8.49. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34.

Insiders Place Their Bets

In other news, Director David M. Demski bought 50,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was acquired at an average price of $5.67 per share, with a total value of $283,500.00. Following the completion of the purchase, the director now directly owns 288,441 shares in the company, valued at $1,635,460.47. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 22.80% of the stock is owned by insiders.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.